Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Motor Activity 1Lymphoma, Follicular 1Colitis, Ulcerative 1

Interventions

etrolizumab 5Infliximab 4Adalimumab 3golimumab 2CT-P13 2peficitinib 1Sutures 1Surgical Instruments 1Ringer's Lactate 1Proctectomy 1Pneumococcal Vaccines 1Papillomavirus Vaccines 1Methylprednisolone 1Mesalamine 1Lysine Acetyltransferase 5 1Laparoscopy 1Injections 1Hydroxyethyl Starch Derivatives 1Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 1Eicosapentaenoic Acid 1CVD protocol 1ABX464 12-(3',4'-dihydroxyphenyl-1-azo)benzimidazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Colitis, Ulcerative × peficitinib × Clear all
NCT01959282 2019-01-04

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

Janssen Research & Development, LLC

Phase 2 Completed
219 enrolled
Lymphoid

Colitis, Ulcerative, Lymphoma, Follicular, Motor Activity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡